Daqing “Darren” Cai, Ph.D.
Board Member, Indi Molecular
Managing Director, Legend Capital
Dr. Daqing “Darren” Cai joined Legend Capital in May 2011. He is a Managing Director, focusing on healthcare investments. Dr. Cai has led investments in more than twenty Legend Capital companies, including Berry Genomics, Ustar, Shenogen, Cardea, BioHermes, BioNano Genomics, and Innovent.
Prior to joining Legend Capital, he was a Managing Director at SBI-SDJB, a joint venture fund of SBI Group and Beida Jadebird Group. Prior to that, Dr. Cai worked for SinoChem (Hong Kong) and Booz & Co. in senior management positions. Earlier in his career, he served as a board member and CFO of the Beijing Genomics Institute.
Dr. Cai holds a Ph.D. degree from the University of California, Berkeley; an MBA from Yale University; and a B.S. degree from University of Science and Technology of China.